RxDoctor Payments Data

Donna Wyatt, MD

Family Medicine · Bossier City, LANPI 1962606558

Payments from drug & device makers

$1,448in general payments, 2019–2025

Across 81 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$275
  • Lilly USA, LLC$270
  • AstraZeneca$215
  • AbbVie$147
  • GSK$113
  • Takeda Pharmaceuticals U.S.A., Inc.$109
  • plus $320 from 12 others

What the payments were for

  • Food & beverage$1,41398%
  • Education$352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,448 in reported general payments places this provider in the 60th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$142,043
Medicare patients
292
Services billed
2,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide121$168,138
OzempicSemaglutide84$132,126
JardianceEmpagliflozin47$52,085
TrulicityDulaglutide28$46,222
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$42,307
EliquisApixaban21$29,951
XareltoRivaroxaban29$23,338
MyrbetriqMirabegron17$17,072
LinzessLinaclotide16$17,018
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$15,956
FarxigaDapagliflozin Propanediol13$12,330
Breo ElliptaFluticasone/Vilanterol21$9,146
Emgality PenGalcanezumab-Gnlm13$8,408
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$5,184
AbrysvoRsv Vacc, Pref A And Pref B/Pf14$4,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$270$214,360149 claims
Novo NordiskOzempic$275$132,12684 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$113$54,01964 claims
Boehringer IngelheimJardiance$26$52,08547 claims
PfizerEliquis, Abrysvo$30$34,40535 claims
AbbVieLinzess, Synthroid$147$20,25963 claims
Astellas Pharma US IncMyrbetriq$34$17,07217 claims
AstraZenecaFarxiga$215$12,33013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →